Sight Sciences, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Sight Sciences reported Q2 2026 revenue of $23.4M (+20% YoY vs $19.6M). Interventional Glaucoma revenue was $20.7M (+8% YoY); Interventional Dry Eye revenue surged to $2.7M (+704% YoY from $0.3M). The company raised FY2026 revenue guidance to $88–$92M (from $83–$89M); reduced adjusted operating expense guidance to $92–$94M (from $93–$96M). Cash position: $79.8M as of June 30, 2026. Key wins: Aetna added ~25M commercial covered lives for glaucoma procedures (retroactive July 14, 2026); IDE patient lives expanded from 10.4M to 14.5M following updated Medicare CPT reimbursement. FDA cleared OMNI Ultra. Net loss improved 63% to $4.4M vs $11.9M prior year.
Why this rating
Strong sequential revenue growth, significant IDE ramp, major payer coverage win (Aetna 25M lives), improved profitability, and raised guidance are material. Relative to $153.6M market cap, Q2 $23.4M run-rate (~$93M annualized midpoint) represents ~61% of current valuation—trajectory-changing if sustained.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.